Clinical trials: Hypertrophy
Nasal Obstruction Due to Inferior Turbinate Hypertrophy
Post-Market Clinical Study to Evaluate the Safety and Effectiveness of REFLEX ULTRA 45 for Coblation Inferior Turbinate Reduction in China
The study is a prospective, multi-center, post-market clinical study to evaluate the safety and effectiveness of REFLEX ULTRA 45 for the coblation inferior turbinate reduction in China.
- Trial name
- NCT07025304
- Testing
- REFLEX ULTRA 45
- Where
- 6 sites in China
- Volunteers
- 105 people
- Sponsor
- Smith & Nephew, Inc.
Benign Prostate Hypertrophy(BPH), Renal Calculi
Stone and Laser Therapies Post-Market Study (SALT)
The objective of the SALT Study is to obtain post-market safety and device performance data for Boston Scientific's Stone and BPH study devices used during a diagnostic and/or therapeutic urinary tract procedure (e.g.…
- Conditions
- Benign Prostate Hypertrophy(BPH), Renal Calculi, Ureteral Stones, Kidney Stones, Calculi, Urinary
- Trial name
- SALT (NCT06982235)
- Testing
- Ureteroscope system, Laser system
- Where
- 5 sites in United States
- Volunteers
- 238 people
- Sponsor
- Boston Scientific Corporation
Danon Disease
A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease
This is a single arm Phase 2 trial to evaluate the efficacy and safety of RP-A501, a recombinant adeno-associated virus serotype 9 (rAAV9) vector containing the human lysosome-associated membrane protein 2 isoform B (LAMP2B)…
- Trial name
- NCT06092034
- Testing
- RP-A501
- Where
- 6 sites in United States, Germany and 2 more
- Volunteers
- 18 people
- Sponsor
- Rocket Pharmaceuticals Inc.
Cardiac Glycogenosis, Cardiomyopathy
ATR 1072 in Participants With PRKAG2 Syndrome
ATR 1072 is an investigational medicine being studied in adults with PRKAG2 Syndrome. This study will evaluate the safety of ATR 1072 and how the body processes the drug.
- Conditions
- Cardiac Glycogenosis, Cardiomyopathy, Hypertrophic, Wolff-Parkinson-White Syndrome
- Trial name
- NCT07738107
- Testing
- ATR 1072
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Atrium Therapeutics
Acne, Acne Scars - Mixed Atrophic and Hypertrophic
AVAVA MIRIA General Use
A general protocol to treat a variety of dermatologic conditions and collect patient feedback. Primary outcome is the collection and analysis of patient questionnaires related to the overall experience of the device treatment.
- Conditions
- Acne, Acne Scars - Mixed Atrophic and Hypertrophic, Scars, Wrinkle
- Trial name
- NCT06868615
- Testing
- AVAVA
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- AVAVA, Inc.
Friedreich Ataxia, Cardiomyopathy, Secondary
Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy
The purpose of Study LX2006-03, a multicenter, Phase 2, open-label, randomized, controlled study, is to evaluate the efficacy and safety of LX2006 gene therapy in participants with Friedreich ataxia (FA) cardiomyopathy (CM).
- Trial name
- SUNRISE-FA 2 (NCT07721025)
- Testing
- LX2006, Usual Care
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Lexeo Therapeutics
Heart Failure With Preserved Ejection Fraction, Concentric Hypertrophy
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
FIRE-HFpEF is a multi-center, prospective, randomized, single-blinded, clinical feasibility study. This study will enroll up to 105 subjects with heart failure with preserved ejection fraction in the United States.
- Trial name
- FIRE-HFpEF (NCT05839730)
- Testing
- Pacemaker PLR + TRT ON, Pacemaker non-pacing mode or an exertional rate-adaptive pacing mode with no planned pacing at rest.
- Where
- 8 sites in United States
- Volunteers
- 105 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Acute Urinary Retention, Benign Prostate Hypertrophy(BPH)
Study of Teverelix DP on Prostate Volume, Urinary Function and Clinical Outcomes Following Acute Urinary Retention
This randomized, double-blind, placebo-controlled Phase 2 study is evaluating Teverelix DP in men following a first episode of acute urinary retention (AUR) associated with benign prostatic hyperplasia (BPH), a population at risk…
- Trial name
- NCT07733934
- Testing
- Teverelix DP
- Volunteers
- 126 people
- Sponsor
- Antev Ltd.
Benign Prostate Hypertrophy(BPH)
A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846
A Clinical trial to compare and evaluate evaluate the pharmacokinetics and safety of CKD-846
- Trial name
- NCT07404735
- Testing
- CKD-846, D091
- Where
- South Korea
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Tonsillar Hypertrophy, Upper Airway Obstruction
Safety and Efficacy of the Irreversible Electroporation (IRE) System for Adenotonsillar Hypertrophy in Children
This is a multi-center, prospective, open-label, traditional feasibility study with a before-after study design. The study is designed to evaluate the safety and efficacy of an Irreversible Electroporation (IRE) System for the…
- Trial name
- NCT06960239
- Testing
- IRE System
- Where
- 2 sites in Romania, Uzbekistan
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- ENTire Medical Ltd.
Haemophilia A (Moderate or Severe), Hemophilia, Classic
A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis
The rationale for conducting this open-label phase 4 study is to assess whether once-weekly prophylaxis with efanesoctocog alfa (50 IU/kg) improves the disease course of existing synovial hypertrophy and prevents the risk of…
- Conditions
- Haemophilia A (Moderate or Severe), Hemophilia, Classic, Haemophilia, Hemophilia
- Trial name
- NCT06752850
- Testing
- Efanesoctocog alfa
- Where
- 10 sites in Italy, Norway and 2 more
- Volunteers
- 37 people
- Sponsor
- Swedish Orphan Biovitrum
Tonsillar Hypertrophy
Efficacy and Safety of Irreversible Electroporation for Chronic Symptomatic Tonsillar Hypertrophy Treatment
The purpose of the IRE System is to address the clinical need for reducing the volume of chronic symptomatic hypertrophic tonsil(s) while minimizing side effects and complications. Procedure time will also be reduced.
- Trial name
- NCT06187194
- Testing
- IRE System
- Where
- Romania
- Volunteers
- 24 people
- Sponsor
- ENTire Medical Ltd.
Inferior Turbinate Hypertrophy, Nasal Obstruction
Efficacy And Safety of An IRE System For Treatment of Inferior Turbinate Hypertrophy
The purpose of the IRE System is to address the clinical need for reducing the volume of hypertrophic inferior turbinate(s) causing nasal obstruction while minimizing side effects and complications.
- Conditions
- Inferior Turbinate Hypertrophy, Nasal Obstruction, Turbinate; Hypertrophy Mucous Membrane
- Trial name
- NCT06438185
- Testing
- IRE System
- Where
- 4 sites in Israel, Lithuania and 2 more
- Volunteers
- 48 people
- Sponsor
- ENTire Medical Ltd.
Benign Prostate Hypertrophy(BPH)
A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846
A Clinical trial to compare and evaluate evaluate the pharmacokinetics and safety of CKD-846
- Trial name
- NCT06110923
- Testing
- CKD-846, D091
- Where
- South Korea
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Labia Enlarged, Labium; Hypertrophy
Evaluation of the Use of the Renuvion APR System in the Labia
Labiaplasty is a procedure aimed at reducing lax or loose skin in the labia majora and/or minora due to childbirth, trauma, aging, genetics, or congenital disease.
- Trial name
- NCT05323630
- Testing
- Renuvion APR System
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Apyx Medical
Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy
Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter
A prospective, non-randomized study. The subjects will be enrolled and treated with the Optilume BPH Prostatic DCB Dilation Catheter System at up to 8 clinical sites. The post-treatment follow-up visit can be up to 5 years.
- Trial name
- EVEREST-I (NCT03423979)
- Testing
- Optilume™ BPH Prostatic DCB Dilation Catheter, Paclitaxel
- Where
- 5 sites in Dominican Republic, Panama
- Volunteers
- 80 people
- Sponsor
- Urotronic Inc.
HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF
US Benchmarking Clinical Study
The goal of this observational study is to measure shear wave velocity (SWV) in patients with non-reduced left ventricular ejection fraction (LVEF) heart failure and left ventricular hypertrophy, with or without transthyretin…
- Conditions
- HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF, ATTR-CM (Transthyretin Amyloid Cardiomyopathy), Left Ventricular Hypertrophy
- Trial name
- EMS-CT-1 (NCT07215715)
- Where
- 3 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- eMyosound SAS
Acne Scars - Mixed Atrophic and Hypertrophic
The MIRIA Acne Scar Study
This study is being conducted to evaluate the performance and efficacy of the AVAVA MIRIA Laser Skin System treatment on acne scars.
- Trial name
- MIRIA (NCT05597267)
- Testing
- MIRIA Laser
- Where
- 3 sites in United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- AVAVA, Inc.
Wrinkle, Acne Scars - Mixed Atrophic and Hypertrophic
AV-23-001 AVAVA MIRIA Pilot Study
This non-significant risk study is intended to demonstrate the use of the MIRIA Skin Treatment System can show improvement in dermatologic conditions currently indicated for treatment with a laser (such as, but not limited to…
- Conditions
- Wrinkle, Acne Scars - Mixed Atrophic and Hypertrophic, Pigmented Lesions, Skin Laxity
- Trial name
- NCT06557434
- Testing
- MIRIA
- Where
- 2 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- AVAVA, Inc.
Wrinkle, Acne Scars - Mixed Atrophic and Hypertrophic
Functional Usability and Feasibility Testing of the Profound Matrix™ System
This is a non-randomized, multi-center, open-label clinical trial evaluating the efficacy and clinical feasibility of the Profound Matrix device for electrocoagulation and for treatment of wrinkles and acne scars.
- Trial name
- NCT06192550
- Testing
- Profound Matrix™ System
- Where
- 5 sites in United States, Israel
- Volunteers
- 193 people, healthy volunteers welcome
- Sponsor
- Candela Corporation